drugset
drugset / Trial / NCT05390944

An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition

NCT05390944 ↗

Phase 1 Completed 28 enrolled Impact Therapeutics, Inc.
RandomizedCrossoverOpen-labelOther

Summary

An open-label, randomized, single-dose, two-way crossover bioequivalence study to compare two strengths (10 mg and 20 mg) of IMP4297 capsules in healthy Chinese subjects under fasting condition.

Timeline

Start
2022-06-08
Primary completion
2022-08-01
Completion
2022-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject IMP4297 Unknown 10 mg Oral
Subject IMP4297 Unknown 20 mg Oral

Indications

cancer